Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Analysts gave Abbott Laboratories a "Moderate Buy" average rating, showing solid support but with a side of cautious optimism ...

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the FRESH-UP ...

In response to a study that found heavy metals in infant formulas, the FDA stated it will bolster its testing of infant ...

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s ...

On Thursday, analysts from Oppenheimer gave the company an “outperform” rating and a price target of $134, a 2-percent upside ...

Abbott Laboratories snagged a CE mark for its Volt pulsed field ablation catheter for atrial fibrillation several months earlier than the mid-year approval expected. The Abbott Park, Ill.-based ...

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...